HC Wainwright Reaffirms “Buy” Rating for Alpha Tau Medical (NASDAQ:DRTS)

HC Wainwright reaffirmed their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $9.00 price objective on the stock.

Separately, Piper Sandler restated an overweight rating and issued a $7.00 price objective on shares of Alpha Tau Medical in a report on Thursday, August 15th.

Alpha Tau Medical Trading Down 2.2 %

NASDAQ:DRTS opened at $2.20 on Friday. The company has a market cap of $153.28 million, a P/E ratio of -5.37 and a beta of 0.77. Alpha Tau Medical has a twelve month low of $1.75 and a twelve month high of $3.90. The business has a 50 day moving average price of $2.26 and a two-hundred day moving average price of $2.38. The company has a quick ratio of 11.60, a current ratio of 11.66 and a debt-to-equity ratio of 0.07.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Wednesday, August 14th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. As a group, analysts expect that Alpha Tau Medical will post -0.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Alpha Tau Medical

A number of institutional investors have recently added to or reduced their stakes in DRTS. USAdvisors Wealth Management LLC acquired a new stake in Alpha Tau Medical in the first quarter valued at $30,000. Aptus Capital Advisors LLC lifted its stake in Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. Financial Guidance Group Inc. lifted its stake in Alpha Tau Medical by 83.7% in the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the last quarter. Caprock Group LLC bought a new position in Alpha Tau Medical during the second quarter worth about $59,000. Finally, Levin Capital Strategies L.P. increased its position in Alpha Tau Medical by 2.6% during the first quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after buying an additional 8,641 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors and hedge funds.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.